Literature DB >> 30482950

Phosphatases start shedding their stigma of undruggability.

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30482950     DOI： 10.1038/nrd.2018.201

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  22 in total

1.  Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.

Authors:  Dominic Maggio; Winson S Ho; Rebecca Breese; Stuart Walbridge; Herui Wang; Jing Cui; John D Heiss; Mark R Gilbert; John S Kovach; Rongze O Lu; Zhengping Zhuang
Journal:  J Neurooncol       Date:  2020-04-27       Impact factor: 4.130

2.  Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.

Authors:  Jiawan Wang; Kai Pollard; Amy N Allen; Tushar Tomar; Dirk Pijnenburg; Zhan Yao; Fausto J Rodriguez; Christine A Pratilas
Journal:  Cancer Res       Date:  2020-10-08       Impact factor: 12.701

Review 3.  Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.

Authors:  Aaron D Krabill; Zhong-Yin Zhang
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

Review 4.  Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.

Authors:  Jiao Kong; Ya-Qiu Long
Journal:  RSC Med Chem       Date:  2022-01-15

5.  Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.

Authors:  Elif Karaca Atabay; Carmen Mecca; Qi Wang; Chiara Ambrogio; Ines Mota; Nina Prokoph; Giulia Mura; Cinzia Martinengo; Enrico Patrucco; Giulia Leonardi; Jessica Hossa; Achille Pich; Luca Mologni; Carlo Gambacorti-Passerini; Laurence Brugières; Birgit Geoerger; Suzanne D Turner; Claudia Voena; Taek-Chin Cheong; Roberto Chiarle
Journal:  Blood       Date:  2022-02-03       Impact factor: 22.113

Review 6.  The expanding role for small molecules in immuno-oncology.

Authors:  Rienk Offringa; Lisa Kötzner; Bayard Huck; Klaus Urbahns
Journal:  Nat Rev Drug Discov       Date:  2022-08-18       Impact factor: 112.288

7.  Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.

Authors:  Xianming Zhou; Chao Zhang; Fei Xie; Wei Wei; Rui Li; Qian Xu; Yu Wang; Philip A Klenotic; Goutham Narla; Nianguo Dong; Zhiyong Lin
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 8.  A comprehensive review of SHP2 and its role in cancer.

Authors:  Moges Dessale Asmamaw; Xiao-Jing Shi; Li-Rong Zhang; Hong-Min Liu
Journal:  Cell Oncol (Dordr)       Date:  2022-09-06       Impact factor: 7.051

9.  BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

Authors:  Marco H Hofmann; Michael Gmachl; Juergen Ramharter; Fabio Savarese; Daniel Gerlach; Joseph R Marszalek; Michael P Sanderson; Dirk Kessler; Francesca Trapani; Heribert Arnhof; Klaus Rumpel; Dana-Adriana Botesteanu; Peter Ettmayer; Thomas Gerstberger; Christiane Kofink; Tobias Wunberg; Andreas Zoephel; Szu-Chin Fu; Jessica L Teh; Jark Böttcher; Nikolai Pototschnig; Franziska Schachinger; Katharina Schipany; Simone Lieb; Christopher P Vellano; Jonathan C O'Connell; Rachel L Mendes; Jurgen Moll; Mark Petronczki; Timothy P Heffernan; Mark Pearson; Darryl B McConnell; Norbert Kraut
Journal:  Cancer Discov       Date:  2020-08-19       Impact factor: 39.397

10.  Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.

Authors:  Evan K Day; Qing Zhong; Benjamin Purow; Matthew J Lazzara
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.